Aligos Therapeutics (NASDAQ:ALGS – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a report released on Friday, Benzinga reports. They currently have a $75.00 price target on the stock.
Aligos Therapeutics Trading Down 28.1 %
Shares of NASDAQ ALGS opened at $10.18 on Friday. The firm has a market capitalization of $795.16 million, a PE ratio of -7.95 and a beta of 2.18. The firm’s 50-day moving average is $13.26 and its 200-day moving average is $16.41. Aligos Therapeutics has a 1 year low of $8.70 and a 1 year high of $30.00.
Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of ($4.00) by $4.75. Aligos Therapeutics had a negative net margin of 1,100.48% and a negative return on equity of 110.59%. The company had revenue of $1.06 million for the quarter. During the same period in the prior year, the business earned ($10.75) earnings per share. As a group, equities research analysts anticipate that Aligos Therapeutics will post -8.15 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
About Aligos Therapeutics
Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).
Featured Stories
- Five stocks we like better than Aligos Therapeutics
- How to Evaluate a Stock Before Buying
- Triple Witching: The Market’s Quarterly Rollercoaster
- Stock Splits, Do They Really Impact Investors?
- 4 Stocks Set to Benefit from Recent Interest Rate Cuts
- How to Buy Cheap Stocks Step by Step
- Autohome’s Dividend and Buyback Make It a Strong EV Play
Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.